About Us
Focus Area
Pipeline
Clinical Trials
Careers
Investors and Media
More
Roxadustat for Chemotherapy-Induced Anemia in Patients with Non-Myeloid Malignancies: A Randomized, Open-Label, Active-Controlled, Phase III Study
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study
Roxadustat for the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients Not on Dialysis: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ALPS)
Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES)
A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer
Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Pamrevlumab, An Anti-Connective Tissue Growth Factor Therapy, For Idiopathic Pulmonary Fibrosis (PRAISE): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial
Pamrevlumab In Idiopathic Pulmonary Fibrosis
Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis
FG-3019, a Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Journal of Cancer Clinical Trials
FG-3019, A Human Monoclonal Antibody Targeting connective tissue Growth Factor, is Subject to Target-Mediated Drug Disposition
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF
Connective tissue growth factor regulates cardiac function and tissue remodeling in a mouse model of dilated cardiomyopathy
FG-3165 is a Novel Galectin-9 Neutralizing Antibody that Inhibits Galectin-9-Mediated Dimerization of TIM-3 and Galectin-9-Induced Apoptosis of CD4+ and CD8+ T Cells
Explore Our Pipeline
